Below are links to view the quarterly newsletter Targeting Trends. You can also download the full PDF here. If you would like to be added to the mailing list, please complete the information on our contact page. The cover article is contributed by this year’s winner of ATS’ SFN Poster of the Year. Aaron Kucinski summarizes […]
The ZAP Sulforhodamine B (SrB; Cat. #KIT-SrB-Z) Development kit contains all of the materials needed to introduce a quantitative staining assay to your lab. Preferred by the National Cancer Institute for high-throughput drug screening, SrB quantitatively stains cellular proteins in an accurate and reproducible manner. Refined and honed over years of use in testing Saporin-conjugate […]
Q: Our lab is getting ready to begin a project using one of your targeted toxins. We already did a preliminary experiment to try out the material, but we have a couple of questions before we start the larger project. First, do you have any protocols or references for injecting intrathecally? A: Thank you for […]
The rate of fall of blood glucose determines the necessity of forebrain-projecting catecholaminergic neurons for male rat sympathoadrenal responses. Jokiaho AJ, Donovan CM, Watts AG. Diabetes 63(8):2854-2865, 2014. Different sets of glucosensors detect insulin-induced hypoglycemia depending on the onset rate. This detection controls the activation of sympathoadrenal counterregulatory responses (CRRs). Slow onset hypoglycemia, common with […]
A groundbreaking pain therapeutic is poised for conditional approval in 2015 to treat bone cancer pain in dogs. The FDA has already approved Minor Use/Minor Species (MUMS) designation for the drug, providing extended market exclusivity to treat the >10,000 annual cases of canine bone cancer-related pain, and the ability to commercialize the drug as soon […]
Congratulations to Dr. Kucinski as this year’s winner of the SfN Poster of the Year Award for the most interesting work presented using ATS products. You can read a summary of this work from Dr. Sarter’s lab in the cover article in this issue of Targeting Trends. Here is a small sample of the comments […]
by Aaron Kucinski (Collaborators at University Michigan, Ann Arbor: K. Phillips, R. Albin, M. Sarter) In addition to the primary disease-defining symptoms that result from extensive loss of nigrostriatal dopaminergic neurons, approximately half of patients with Parkinson’s Disease (PD) suffer from postural instability, impairments in gait control and a propensity for falls. These symptoms have […]